MARCHESELLI, Raffaella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.899
EU - Europa 2.833
AS - Asia 2.429
SA - Sud America 338
AF - Africa 80
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 5
Totale 11.599
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.791
GB - Regno Unito 1.304
SG - Singapore 736
CN - Cina 677
IT - Italia 359
HK - Hong Kong 304
VN - Vietnam 251
DE - Germania 250
BR - Brasile 237
SE - Svezia 223
FR - Francia 147
FI - Finlandia 127
RU - Federazione Russa 112
UA - Ucraina 108
IN - India 76
TR - Turchia 74
CA - Canada 54
KR - Corea 52
BD - Bangladesh 43
BG - Bulgaria 43
ID - Indonesia 40
MA - Marocco 40
AR - Argentina 39
IQ - Iraq 30
MX - Messico 24
BE - Belgio 20
ES - Italia 19
PL - Polonia 19
NL - Olanda 18
EC - Ecuador 16
PK - Pakistan 16
AE - Emirati Arabi Uniti 15
CO - Colombia 14
IE - Irlanda 14
ZA - Sudafrica 14
AU - Australia 13
CH - Svizzera 13
CZ - Repubblica Ceca 13
JP - Giappone 12
MY - Malesia 11
SA - Arabia Saudita 10
UZ - Uzbekistan 10
AT - Austria 9
IR - Iran 9
VE - Venezuela 9
AZ - Azerbaigian 8
CL - Cile 8
LT - Lituania 8
PH - Filippine 8
HU - Ungheria 7
DO - Repubblica Dominicana 6
JO - Giordania 6
PY - Paraguay 6
BZ - Belize 5
CR - Costa Rica 5
JM - Giamaica 5
KE - Kenya 5
KG - Kirghizistan 5
KZ - Kazakistan 5
DK - Danimarca 4
TH - Thailandia 4
TN - Tunisia 4
BO - Bolivia 3
EG - Egitto 3
EU - Europa 3
GP - Guadalupe 3
LB - Libano 3
NO - Norvegia 3
NP - Nepal 3
PS - Palestinian Territory 3
UY - Uruguay 3
BH - Bahrain 2
CY - Cipro 2
ET - Etiopia 2
IL - Israele 2
KH - Cambogia 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
PA - Panama 2
PE - Perù 2
PT - Portogallo 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
TZ - Tanzania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BF - Burkina Faso 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
Totale 11.584
Salva come PNG Salva come JPEG
Città #
Southend 1.070
Ashburn 620
Fairfield 592
Santa Clara 508
Singapore 485
Woodbridge 458
Hong Kong 297
Houston 276
Chandler 269
Seattle 246
Wilmington 222
Ann Arbor 206
Cambridge 205
Jacksonville 203
Beijing 192
San Jose 176
Dearborn 163
Nyköping 162
Hefei 138
London 114
New York 108
Modena 97
Chicago 80
Helsinki 78
Los Angeles 78
Ho Chi Minh City 70
Frankfurt am Main 66
The Dalles 62
Council Bluffs 61
San Diego 57
Hanoi 50
Seoul 49
Shanghai 43
Princeton 42
Sofia 42
Munich 39
Eugene 38
Moscow 36
Milan 35
Salt Lake City 35
Casablanca 32
Lauterbourg 32
Izmir 30
Buffalo 27
Bremen 26
Bologna 25
Jakarta 24
São Paulo 21
Columbus 20
Brussels 19
Dallas 19
Elk Grove Village 19
Montreal 19
Da Nang 17
Redwood City 17
Warsaw 17
Falls Church 16
Orem 16
Phoenix 16
Turku 15
Dublin 14
New Delhi 14
Rome 14
Boardman 13
Denver 13
Des Moines 13
Nanjing 13
Fremont 12
Guangzhou 12
Manchester 12
Tampa 12
Baghdad 11
Brooklyn 11
Poplar 11
Tokyo 11
Buenos Aires 10
Chennai 10
Dong Ket 10
Paris 10
Boston 9
Kunming 9
Norwalk 9
Ottawa 9
Rho 9
Toronto 9
Gurugram 8
Indiana 8
San Giuliano Milanese 8
San Mateo 8
Sterling 8
Stockholm 8
Tashkent 8
Baku 7
Carpi 7
Dhaka 7
Johannesburg 7
Lahore 7
Nuremberg 7
Quito 7
Turin 7
Totale 8.587
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 608
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 508
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 426
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 399
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 375
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 359
Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy 337
A concise review of lenalidomide therapy for follicular lymphoma 336
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 328
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 317
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 315
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 304
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 304
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 299
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 296
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 295
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 295
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 291
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 283
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 279
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 279
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 272
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 270
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 269
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 268
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 263
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 263
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 255
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 254
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 244
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 240
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 234
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 229
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 227
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 218
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 216
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 205
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 178
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 169
Epidemiologia degli infortuni lavorativi in minori: risultati di una indagine condotta nella città di Modena nel periodo gennaio-giugno 2000. 166
Totale 11.673
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.526
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.526
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021368 0 0 0 0 0 0 0 0 0 114 176 78
2021/2022874 30 86 80 49 24 74 49 50 107 61 156 108
2022/2023854 92 111 60 78 98 118 26 87 93 10 55 26
2023/2024683 24 26 49 63 145 59 146 48 17 16 35 55
2024/20251.761 66 19 42 121 373 276 124 108 195 56 140 241
2025/20263.136 241 144 204 385 586 222 446 171 369 368 0 0
Totale 11.673